분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2018-11-14 15:47:56 , Hit : 33
 Keytruda Gets FDA Approval for Hepatocellular Carcinoma

https://www.empr.com/news/keytruda-pembrolizumab-liver-cancer-previously-treated-sorafenib-approval/article/814060/

MPR >  News >  Keytruda Gets FDA Approval for Hepatocellular Carcinoma

Diana Ernst, RPh
November 12, 2018


Keytruda is a programmed death receptor-1 (PD-1) blocking antibody
Keytruda is a programmed death receptor-1 (PD-1) blocking antibody

The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

The approval was based on data from the KEYNOTE-224 study, a single-arm trial in patients with HCC who had disease progression on or after sorafenib or were intolerant to sorafenib; had measurable disease; and had Child-Pugh class A liver impairment. Patients (N=104) were treated with Keytruda 200mg intravenously every 3 weeks until unacceptable toxicity, investigator-assessed confirmed disease progression, or completion of 24 months of therapy; the primary efficacy measures were overall response rate (ORR) and duration of response according to RECIST v1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, as assessed by blinded independent central review.

Results showed an ORR of 17% (95% CI, 11–26), with 1% of patients having a complete response and 16% of patients having a partial response. A duration of response of ≥6 months and ≥12 months was observed in 89% and 56% of patients who responded to treatment (N=18), respectively; the median duration of exposure was 4.2 months.

Continued approval of Keytruda for HCC may be contingent upon verification and description of clinical benefit in confirmatory trials as the indication was approved under the accelerated approval pathway based on tumor response rate and durability of response.



Related Articles
Long-Term Aspirin Use May Reduce Liver Cancer Risk
Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Cabozantinib Improves Survival in Advanced Hepatocellular Cancer


Keytruda, a programmed death receptor-1 (PD-1) blocking antibody, is also approved for the treatment of melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high cancer, gastric cancer, and cervical cancer.

For more information visit Merck.com.







1261   Second CRISPR-Modified Pregnancy May Be Underway  이성욱 2018/11/30 21
1260   Human Genome Editing Committee Urges Halt in Germline Editing Trials  이성욱 2018/11/30 14
1259   [바이오토픽] 중국, 최초의 유전체편집 아기 탄생  이성욱 2018/11/27 15
  Keytruda Gets FDA Approval for Hepatocellular Carcinoma  이성욱 2018/11/14 33
1257   Novel Two-Pronged Method Targets Cancer Cells’ Telomerase and Chromosomes  이성욱 2018/11/03 38
1256   Expanding the reach of gene editing with a new CRISPR enzyme  이성욱 2018/10/26 49
1255   분자수준 인체 간세포 지도 처음 작성  이성욱 2018/10/24 33
1254   RNA-Based Gene Therapy Can Be Turned ON or OFF via Synbio Switches  이성욱 2018/10/18 33
1253   CRISPR Enhancement Cures Genetic Disease in Mice  이성욱 2018/10/10 35
1252   [바이오토픽] 구관이 명관, CRISPR가 만능은 아니다  이성욱 2018/10/08 53
1251   Checkpoint Inhibitor Generated by Synthetic DNA in Vivo  이성욱 2018/10/06 33
1250   Frances H. Arnold, George P. Smith, and Gregory P. Winter share 2018 Nobel Prize in Chemistry  이성욱 2018/10/04 29
1249   Immunotherapy Pioneers Take 2018 Nobel Prize  이성욱 2018/10/02 32
1248   2018 Lasker Award Winners: Gene Expression Researchers, Propofol Discoverer, Pioneer for RNA Biology, and Women in STEM  이성욱 2018/09/12 62
1247   [바이오토픽] CRISPR 특허전쟁 항소심, 브로드 연구소 승리  이성욱 2018/09/11 54
1246   Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma  이성욱 2018/08/19 80
1245   [바이오토픽] 유전자를 침묵시키는 신약, 20년의 기다림 끝에 승인  이성욱 2018/08/13 80
1244   Doubts arise again about CRISR'd human embryos  이성욱 2018/08/09 85
1243   CRISPR-Cas12a More Precise Than CRISPR-Cas9  이성욱 2018/08/07 90
1242   Lethal Viruses Hijack DNA-Damage Response, May Be Exploited for Cancer  이성욱 2018/08/07 90

1 [2][3][4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2018 Zeroboard / skin by ROBIN